However, while long‐term stabilization and partial tumor responses are observed in PIK3CA‐positive breast cancers treated with PI3Ki (NCT01219699) (Brana and Siu, 2012), the majority of mutant cancers do not experience substantial regression (Bendell et al., 2012). Here, PIK3CA is linked to breast carcinoma.